Chinese oncology company Genetron Health reported on Thursday the receipt of approval from China's National Medical Products Administration for the launch of GENETRON S5 for clinical use.

GENETRON S5 can be used in early screening, diagnosis, treatment guidance and continuous monitoring with assays for gliomas, lung cancer, urothelial cancer, breast cancer and thyroid cancer.

A semiconductor-based next generation sequencing (NGS) system, GENETRON S5 detects changes in pH value in nucleotides. It does not require fluorescence or camera scanning, resulting in faster, simpler and more cost-effective tests with a smaller sample size, the company said.

According to Genetron Health, GENETRON S5 leverages high speed semiconductor sequencing technology to produce high-quality sequencing data, enabling laboratory technicians to go from DNA library to data in as little as 24 hours. This is based on its patented One-Step Seq Method, which facilitates the preparation of high-quality libraries in less than two hours from as little as 10ng input samples.